New Drug Tirzepatide Shows Promise for Glucose Control, Weight Loss

Tirzepatide, a new once-weekly GIP/GLP-1 medication, is now in phase 3 testing for blood glucose management and chronic weight management in individuals with type 2 diabetes. GIP is a hormone that may help GLP-1 receptor agonists work better, and has been found in early testing to reduce food intake while increasing energy expenditure, resulting in weight loss. Read more

Posted in Type II Medical Research